<DOC>
	<DOCNO>NCT01170143</DOCNO>
	<brief_summary>To compare efficacy term pathological complete response rate ( pCR ) preoperative administration qw q3w Paclitaxel , Carboplatin Trastuzumab ( PCH )</brief_summary>
	<brief_title>Efficacy Safety Study Trastuzumab , Paclitaxel Carboplatin HER2+ Preoperative Breast Cancer</brief_title>
	<detailed_description>Currently Herceptin move Neoadjuvant treatment combine chemotherapy . Paclitaxel Carboplatin two best partner high pCR . The significant efficacy good safety profile Herceptin® combination taxane adjuvant treatment EBC accept ; 1 year Herceptin adjuvant treatment one standard therapy . This study one small Phase II trial explore efficacy safety QW Q3W PCH Neoadjuvant treatment , plan 60 pt trend two curve anticipate</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Women age equal 18 year 70 year life expectancy 12 month 2 . Histologically confirm invasive breast cancer ( exclude inflammatory breast cancer ) core needle biopsy , T2N1 local advance breast cancer , evidence metastasis 3 . HER2 positive confirm FISH/CISH+ IHC 3+ 4 . With history cancer situ uterine cervix cancer skin basal cell carcinoma 5 . Adequate hematopoietic function : Neutrophil large 1.5*109/L ; Hb large 100g/L ; PLT large 100*109/L 6 . Adequate hepatic renal function serum AST le 60U/L Total bilirubin le 1.5 ULN serum creatinine le 110umol/L BUN less 7.1mmol/L 7 . LVEF 55 % MUGA scan echocardiography 8 . Adequate coagulation function 9 . ECOG PS 01 10 . Willing take biopsy surgery chemotherapy willing take preoperative chemotherapy relate treatment 11 . Women childbearing potential must negative pregnancy test ( urine serum ) within 7 day drug administration agree take adequate contraceptive measure 12 . Signed write informed consent ; Able comply protocol 1 . Prior systemic locoregional treatment breast cancer , include chemotherapy 2 . Metastatic breast cancer 3 . Patients medical condition render intolerant neoadjuvant therapy relate treatment , include uncontrolled pulmonary disease , Diabetes Mellitus , severe infection , active peptic ulcer , Coagulation disorder , connective tissue disease myelosuppressive disease 4 . History congestive heart failure , uncontrolled symptomatic angina pectoris , arrhythmia myocardial infarction ; poorly control hypertension ( Systolic BP 180mmHg Diastolic BP 100mmHg） 5. grade 1 peripheral neuropathy cause 6 . Patient pregnant nursing 7 . Not willing take preoperative biopsy neoadjuvant therapy 8 . Patients psychiatric disorder disease lead incompliance therapy 9 . Known hypersensitivity ingredient regimen 10 . Treatment investigational drug within 30 day begin treatment study drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>IIB-IIIB Breast Cancer</keyword>
	<keyword>Her2 positive</keyword>
</DOC>